EGFR Gene Mutation Clinical Trials

61 clinical trials for EGFR Gene Mutation across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells — RECRUITING · PHASE1
• Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT — RECRUITING · PHASE2
• EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations — RECRUITING · NA
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy — RECRUITING · PHASE2
• Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. — RECRUITING · NA
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy — RECRUITING
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors — RECRUITING · PHASE2
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis — RECRUITING · NA
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients — RECRUITING · PHASE1
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) — RECRUITING
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation — RECRUITING · PHASE2
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases — RECRUITING · NA
• Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer — COMPLETED · PHASE1
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation — TERMINATED · PHASE1
• In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing — NOT_YET_RECRUITING
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies — COMPLETED · PHASE2
• Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — ACTIVE_NOT_RECRUITING · PHASE2
• An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases — NOT_YET_RECRUITING · PHASE1
• Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies — ACTIVE_NOT_RECRUITING · NA
• Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 — COMPLETED · PHASE2
• Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations — ACTIVE_NOT_RECRUITING · PHASE3
• First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases — COMPLETED · PHASE2
• Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer — COMPLETED · NA
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC — COMPLETED · PHASE2
• A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. — COMPLETED · PHASE1
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients — TERMINATED · PHASE2
• Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC — COMPLETED · PHASE1
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC — TERMINATED · PHASE1
• 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma — COMPLETED · PHASE2
• First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer — COMPLETED · PHASE1
• Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations — TERMINATED · PHASE1
• Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) — TERMINATED · PHASE2
• Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC — NOT_YET_RECRUITING · PHASE2
• Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) — NOT_YET_RECRUITING · PHASE3
• Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability — OTHER · NA
• Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients — COMPLETED · NA
• Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers — OTHER · PHASE2
• The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC — NOT_YET_RECRUITING
• Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment — OTHER · NA
• Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer — COMPLETED · PHASE1
• Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. — NOT_YET_RECRUITING · PHASE2
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC — TERMINATED · PHASE1
• A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC — NOT_YET_RECRUITING · NA
• Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma — COMPLETED · PHASE2
• Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC — OTHER · PHASE2
• Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy — OTHER
• Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA — COMPLETED · PHASE2

Refine this search